Search Results

AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines Agency and the United States Food and Drug Administration have granted orphan drug designation to its lead clinical candidate, AM1476 for the treatment of systemic sclerosis.

AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.

Quantify Medical Sees Initial Success with Venowave VW5 Sales and Medicare/Medicaid Reimbursement Test

The Dana Foundation Launches Neurotech Justice Accelerator at Mass General Brigham (NJAM) to Unite Science and Society and Mitigate Medical, Legal, and Ethical Risks

Medical robotics innovatorNoah Medical today announced the final results from its FRONTIER Study, the platform’s first-in-human clinical trial testing the “Tool-in-Lesion” accuracy of its Galaxy System™, are now available for review in the Official Journal of the Asian Pacific Society of Respirology.